Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...
Associated Press22d
Poland aims to train 100,000 military reservists a year as security fears grow
Copyright 2025 The Associated Press. All Rights Reserved. Polish Prime Minister Donald Tusk speaks at the Sejm, the lower house of parliament, in Warsaw, Poland ...
The Motley Fool23d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
BioPharma Dive28d
Vertex’s new pain drug gets first coverage nod from major insurer
Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals ... “In the interim, Journavx was added to our standard commercial ...